Selected research
Industry Research
Live and Attenuated Vaccine Industry Research Report 2026
Market perspective
The global Live and Attenuated Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Live and Attenuated Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Live and Attenuated Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Live and Attenuated Vaccine include Sanofi, Johnson & Johnson, Merck & Co., Pfizer, Inc, GlaxoSmithKline, Serum Institute, MedImmune, LLC, Emergent BioSolutions, Inc. and CSL Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Live and Attenuated Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Live and Attenuated Vaccine Market by Company
Sanofi
Johnson & Johnson
Merck & Co.
Pfizer, Inc
GlaxoSmithKline
Serum Institute
MedImmune, LLC
Emergent BioSolutions, Inc.
CSL Limited
Astellas Pharma Inc
Live and Attenuated Vaccine Segment by Type
Pediatric Vaccine
Adult Vaccines
Live and Attenuated Vaccine Segment by Application
Clinics
Diagnostic Centers
Hospitals
Research Institute
Others
Live and Attenuated Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live and Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live and Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live and Attenuated Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Live and Attenuated Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Live and Attenuated Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Live and Attenuated Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pediatric Vaccine
- Adult Vaccines
Applications
- Clinics
- Diagnostic Centers
- Hospitals
- Research Institute
- Others
Companies covered
- Sanofi
- Johnson & Johnson
- Merck & Co.
- Pfizer, Inc
- GlaxoSmithKline
- Serum Institute
- MedImmune, LLC
- Emergent BioSolutions, Inc.
- CSL Limited
- Astellas Pharma Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Live and Attenuated Vaccine Market Size (2021-2032)
- 2.2.2 Global Live and Attenuated Vaccine Sales (2021-2032)
- 2.2.3 Global Live and Attenuated Vaccine Market Average Price (2021-2032)
- 2.3 Live and Attenuated Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pediatric Vaccine
- 2.3.3 Adult Vaccines
- 2.4 Live and Attenuated Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinics
- 2.4.3 Diagnostic Centers
- 2.4.4 Hospitals
- 2.4.5 Research Institute
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Live and Attenuated Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Live and Attenuated Vaccine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Live and Attenuated Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Live and Attenuated Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Live and Attenuated Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Live and Attenuated Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Live and Attenuated Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Live and Attenuated Vaccine, Established Date
- 3.9 Global Live and Attenuated Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Live and Attenuated Vaccine Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Live and Attenuated Vaccine Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Merck & Co.
- 4.3.1 Merck & Co. Company Information
- 4.3.2 Merck & Co. Business Overview
- 4.3.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck & Co. Live and Attenuated Vaccine Product Portfolio
- 4.3.5 Merck & Co. Recent Developments
- 4.4 Pfizer, Inc
- 4.4.1 Pfizer, Inc Company Information
- 4.4.2 Pfizer, Inc Business Overview
- 4.4.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer, Inc Live and Attenuated Vaccine Product Portfolio
- 4.4.5 Pfizer, Inc Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Serum Institute
- 4.6.1 Serum Institute Company Information
- 4.6.2 Serum Institute Business Overview
- 4.6.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Serum Institute Live and Attenuated Vaccine Product Portfolio
- 4.6.5 Serum Institute Recent Developments
- 4.7 MedImmune, LLC
- 4.7.1 MedImmune, LLC Company Information
- 4.7.2 MedImmune, LLC Business Overview
- 4.7.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MedImmune, LLC Live and Attenuated Vaccine Product Portfolio
- 4.7.5 MedImmune, LLC Recent Developments
- 4.8 Emergent BioSolutions, Inc.
- 4.8.1 Emergent BioSolutions, Inc. Company Information
- 4.8.2 Emergent BioSolutions, Inc. Business Overview
- 4.8.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio
- 4.8.5 Emergent BioSolutions, Inc. Recent Developments
- 4.9 CSL Limited
- 4.9.1 CSL Limited Company Information
- 4.9.2 CSL Limited Business Overview
- 4.9.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CSL Limited Live and Attenuated Vaccine Product Portfolio
- 4.9.5 CSL Limited Recent Developments
- 4.10 Astellas Pharma Inc
- 4.10.1 Astellas Pharma Inc Company Information
- 4.10.2 Astellas Pharma Inc Business Overview
- 4.10.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio
- 4.10.5 Astellas Pharma Inc Recent Developments
5 Global Live and Attenuated Vaccine Market Scenario by Region
- 5.1 Global Live and Attenuated Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Live and Attenuated Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Live and Attenuated Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Live and Attenuated Vaccine Sales by Region: 2027-2032
- 5.3 Global Live and Attenuated Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Live and Attenuated Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Live and Attenuated Vaccine Revenue by Region: 2027-2032
- 5.4 North America Live and Attenuated Vaccine Market Facts & Figures by Country
- 5.4.1 North America Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Live and Attenuated Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Live and Attenuated Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Live and Attenuated Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Live and Attenuated Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Live and Attenuated Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Live and Attenuated Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Live and Attenuated Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Live and Attenuated Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Live and Attenuated Vaccine Market Facts & Figures by Country
- 5.7.1 South America Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Live and Attenuated Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Live and Attenuated Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Live and Attenuated Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Live and Attenuated Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Live and Attenuated Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Live and Attenuated Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Live and Attenuated Vaccine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Live and Attenuated Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Live and Attenuated Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Live and Attenuated Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Live and Attenuated Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Live and Attenuated Vaccine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Live and Attenuated Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Live and Attenuated Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Live and Attenuated Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Live and Attenuated Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Live and Attenuated Vaccine Value Chain Analysis
- 8.1.1 Live and Attenuated Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Live and Attenuated Vaccine Production Mode & Process
- 8.2 Live and Attenuated Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Live and Attenuated Vaccine Distributors
- 8.2.3 Live and Attenuated Vaccine Customers
9 Global Live and Attenuated Vaccine Analyzing Market Dynamics
- 9.1 Live and Attenuated Vaccine Industry Trends
- 9.2 Live and Attenuated Vaccine Industry Drivers
- 9.3 Live and Attenuated Vaccine Industry Opportunities and Challenges
- 9.4 Live and Attenuated Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst